Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-217 (zuranolone) for relapse prevention in major depressive disorder
2019-002640-25Phase 3Terminated
- Sponsor
- Sage Therapeutics
- Start
- Oct 2019
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zuranolone in major depressive disorder (MDD) (3 arms), sponsored by Sage Therapeutics. Primary endpoint: Time to relapse during double-blind phase. Started Oct 2019; status: terminated.
02
Drugs
zuranolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2019-002640-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002640-25.